Piper Sandler analyst Allison Bratzel reiterated a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $10.00.

IO Biotech announced that it is on track to submit a Biologics License Application for its investigational cancer vaccine Cylembio® to the FDA by the end of 2025, following the completion of ...

IO Biotech has a 52-week low of $0.66 and a 52-week high of $1.85. Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in shares of IO ...

IO Biotech (NASDAQ:IOBT – Get Free Report) is projected to release its earnings data on Tuesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.39) per share for the quarter.

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company ...

IO Biotech's proprietary T-win ® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within the TME.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers. Our ...